semaj83/ctmatch_classification huggingface dataset:
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Type 2 Diabetes Mellitus Patients with type 2 diabetes mellitus on short-term insulin therapy (≤ 12 months); all types of insulin allowed Documented insulin-associated weight gain ≥ 3.0 kg from the start of insulin therapy until Age 18-75 years BMI ≥ 25 kg/m2 Stable glycaemic control mirrored by HbA1c ≥ 6.5 and ≤ 8.5 %  Inability to provide informed consent Type 1 diabetes mellitus, MODY diabetes, or LADA diabetes (presence of anti-GAD) Presence of any medical condition that might interfere with the current study protocol Inflammatory bowel disease (e.g. M. Crohn, ulcerative colitis) Recurrent hypoglycaemic events Diabetic gastroparesis Heart failure (LVEF ≤ 30%) Use of TZDs (glitazones), DDP-IV (dipeptidylpeptidase-inhibitor) Use of medication associated with impaired glucose metabolism including corticosteroids Pregnancy or breast-feeding (contraception of at least 3 months before is required for fertile women)
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-36.0,  Spontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing IUI age ≤ 36 years regular menstrual cycles body mass index (BMI) between 18 and 29 kg/m² basal levels of FSH (≤ 12 IU/l) estradiol (≤ 80 pg/ml) and progesterone (≤ 1.6ng/ml) on day one of the cycle, normal hysterosalpingography (maximum 3 months prior starting the cycle) The use of donor sperm was also accepted as criteria  PCOS endometriosis
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 7.0-18.0,  Hyperandrogenemia Polycystic Ovary Syndrome Obesity Normal and obese (>95th BMI%) females Weight of 24 kg or more Early to late puberty (expected age range 7-18) Screening labs within age-appropriate normal range, with the exception of a mildly low hematocrit (see below) and the hormonal abnormalities inherent in obesity which could mildly elevated LH, lipids, testosterone, prolactin, DHEAS, E2, glucose, and insulin; and decreased follicle-stimulating hormone (FSH) and/or sex hormone-binding globulin (SHBG)  Screening labs outside of age-appropriate normal range Hemoglobin <12 mg/dL and hematocrit<36% (Subjects will be offered the opportunity to take iron supplementation for 60 days if their hematocrit is slightly low (33-36%) (suggestive of iron deficiency anemia) and will then return for retesting of their hemoglobin/hematocrit. If still <36%, they will be excluded.) Morning Cortisol <5 g/dL hydroxyprogesterone >295 ng/dL Weight<24 kg History of Cushing's syndrome or adrenal insufficiency Pregnant (self reported)
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 7.0-18.0,  Polycystic Ovary Syndrome Obesity Hyperandrogenism Girls age 7-18 years Normal weight (BMI 5-85%-ile for age) or overweight (>85%-ile) With or without signs of excess androgen Screening labs within age-appropriate normal range, with the exception of a mildly low hematocrit (see below) and the hormonal abnormalities inherent in obesity which could mildly elevated luteinizing hormone (LH), lipids, testosterone, prolactin, DHEAS, E2, glucose, and insulin; and decreased follicle-stimulating hormone (FSH) and/or sex hormone-binding globulin (SHBG)  Patients currently enrolled in another research protocol will be excluded, except for those enrolled in IRB-HSR #12702/JCM022. This protocol is designed to allow subjects enrolling in IRB-HSR #12702/JCM022 to simultaneously participate in this companion protocol Inability to comprehend what will be done during the study or why it will be done BMI-for-age < 5th percentile Weight < 27 kg if simultaneously participating in IRB-HSR #12702/JCM022 due to blood volume limits Obesity associated with a diagnosed genetic syndrome (e.g. Prader-Willi syndrome) Since the study involves looking at ovarian function, boys will be excluded Positive pregnancy test or lactation. Subjects with a positive pregnancy test will be informed of the result by the screening physician. Under Virginia law, parental notification is not required for minors. However, the screening physician will encourage them to tell their parent(s) and counsel them about the importance of appropriate prenatal care and counseling. We will arrange follow-up for them at the Teen Health Clinic at the University of Virginia or their primary care physician's office in a timely manner Abnormal laboratory studies will be confirmed by repeat testing to laboratory error Morning cortisol < 3 microgram/dL or history of Cushing syndrome or adrenal insufficiency History of congenital adrenal hyperplasia or 17-hydroxyprogesterone > 300 ng/dL, which suggests the possibility of congenital adrenal hyperplasia (if postmenarchal, the 17-hydroxyprogesterone will be collected during the follicular phase, or ≥ 40 days since last menses if oligomenorrheic). NOTE: If a 17-hydroxyprogesterone >300 mg/dL is confirmed on repeat testing, an adrenocorticotropic hormone-stimulated 17-hydroxyprogesterone <1000 ng/dL will be required for study participation
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 7.0-18.0,  Hyperandrogenemia Obesity Polycystic Ovary Syndrome Overweight(>85th BMI%) females Early to late puberty (expected age range 7-18) Hyperandrogenemic (free testosterone greater than 2.5 standard deviations above the mean for normal control subjects of the same Tanner Stage) Screening labs within age-appropriate normal range, with the exception of a mildly low hematocrit (see below) and the hormonal abnormalities inherent in obesity which could mildly elevated luteinizing hormone (LH), lipids, testosterone, prolactin, DHEAS, E2, glucose, and insulin; and decreased follicle-stimulating hormone (FSH) and/or sex hormone-binding globulin (SHBG)  Screening labs outside of age-appropriate normal range Hemoglobin <12 mg/dL and hematocrit<36% (Subjects will be offered the opportunity to take iron supplementation for 60 days if their hematocrit is slightly low (33-36%) (suggestive of iron deficiency anemia) and will then return for retesting of their hemoglobin/hematocrit. If still <36%, they will be excluded.) Morning Cortisol <5 g/dL hydroxyprogesterone >295 ng/dL History of Cushing's syndrome or adrenal insufficiency Pregnant
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 7.0-18.0,  Obesity Hyperandrogenemia Polycystic Ovary Syndrome Overweight(>85th BMI%) females Early to late puberty (expected age range 7-18) Hyperandrogenemic (free testosterone greater than 2.5 standard deviations above the mean for normal control subjects of the same Tanner Stage) Screening labs within age-appropriate normal range, with the exception of a mildly low hematocrit (see below) and the hormonal abnormalities inherent in obesity which could mildly elevated luteinizing hormone (LH), lipids, testosterone, prolactin, DHEAS, E2, glucose, and insulin; and decreased follicle-stimulating hormone (FSH) and/or sex hormone-binding globulin (SHBG)  Age < 7 or > 18 y Inability to comprehend what will be done during the study or why it will be done BMI-for-age < 5th percentile Positive pregnancy test or lactation Abnormal laboratory studies will be confirmed by repeat testing to laboratory error Morning cortisol < 3 µg/dL or history of Cushing syndrome or adrenal insufficiency History of congenital adrenal hyperplasia or 17-hydroxyprogesterone > 300 ng/dL, which suggests the possibility of congenital adrenal hyperplasia (if postmenarcheal, the 17-hydroxyprogesterone will be collected during the follicular phase, or ≥ 40 days since last menses if oligomenorrheic). NOTE: If a 17-hydroxyprogesterone >300 mg/dL is confirmed on repeat testing, an ACTH-stimulated 17-hydroxyprogesterone <1000 ng/dL will be required for study participation Total testosterone > 150 ng/dL, which suggests the possibility of a virilizing neoplasm DHEAS greater than the upper limit of age-appropriate normal range (mild elevations may be seen in polycystic ovary syndrome (PCOS) and adolescent hyperandrogenemia (HA), and elevations < 1.5 times the age-appropriate upper limit of normal will be accepted in these groups) Virilization
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 7.0-18.0,  Obesity Hyperandrogenemia Polycystic Ovary Syndrome Overweight(>85th BMI%) females Early to late puberty (expected age range 7-18) Hyperandrogenemic (free testosterone greater than 2.5 standard deviations above the mean for normal control subjects of the same Tanner Stage) Screening labs within age-appropriate normal range, with the exception of a mildly low hematocrit (see below) and the hormonal abnormalities inherent in obesity which could mildly elevated luteinizing hormone (LH), lipids, testosterone, prolactin, DHEAS, E2, glucose, and insulin; and decreased follicle-stimulating hormone (FSH) and/or sex hormone-binding globulin (SHBG)  Age < 7 or > 18 years Inability to comprehend what will be done during the study or why it will be done BMI-for-age < 5th percentile Positive pregnancy test or lactation Abnormal laboratory studies will be confirmed by repeat testing to laboratory error Morning cortisol < 3 µg/dL or history of Cushing syndrome or adrenal insufficiency History of congenital adrenal hyperplasia or 17-hydroxyprogesterone > 300 ng/dL, which suggests the possibility of congenital adrenal hyperplasia (if postmenarcheal, the 17-hydroxyprogesterone will be collected during the follicular phase, or ≥ 40 days since last menses if oligomenorrheic). NOTE: If a 17-hydroxyprogesterone >300 mg/dL is confirmed on repeat testing, an ACTH-stimulated 17-hydroxyprogesterone <1000 ng/dL will be required for study participation Total testosterone > 150 ng/dL, which suggests the possibility of a virilizing neoplasm DHEAS greater than the upper limit of age-appropriate normal range (mild elevations may be seen in Polycystic Ovary Syndrome (PCOS) and adolescent Hyperandrogenemia (HA), and elevations < 1.5 times the age-appropriate upper limit of normal will be accepted in these groups) Virilization
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 8.0-18.0,  Hyperandrogenemia Polycystic Ovary Syndrome (PCOS) Girls ages 8 to 18 Hyperandrogenemic (testosterone level > 0.4 ng/mL and/or hirsutism) Normal screening labs (with exception of the expected hormonal abnormalities inherent in hyperandrogenemia)  Abnormal screening labs (with exception of the expected hormonal abnormalities inherent in hyperandrogenemia) Congenital adrenal hyperplasia Hemoglobin <12 mg/dL or hematocrit < 36% (Subjects will be offered the opportunity to take iron supplementation for 60 days if their hematocrit is slightly low (33-36%) (suggestive of iron deficiency anemia) and will then return for retesting of their hemoglobin/hematocrit.) Weight < 31 kg History of peanut allergy, deep venous thrombosis, breast cancer, endometrial cancer, or cervical cancer On hormonal medications (including oral contraceptive pills) or on medications known to affect the reproductive axis within 3 months of the study Pregnant or breastfeeding Participation in a research study within the past 30 days that involved taking a study drug Participation in a research study that involved taking up to or greater than 473 ml's of blood within the past 60 days Cigarette smoking
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 10.0-17.0,  Polycystic Ovary Syndrome Hyperandrogenism Girls ages 10 to 17 Hyperandrogenemic (free testosterone greater than 2.5 standard deviations above the mean for normal control subjects of the same Tanner Stage) Creatinine clearance > 90 ml/min as calculated by the Cockcroft-Gault equation Hemoglobin > 12 mg/dL or Hematocrit > 36% Normal screening labs (with exception of the expected hormonal abnormalities inherent in hyperandrogenemia) Sexually active subjects must agree to abstain or use double barrier contraception during the study Subjects must agree not to take any other medications during the course of the study without approval by the study investigators  Abnormal screening labs (with the exception of the expected hormonal abnormalities inherent in hyperandrogenemia) Creatinine clearance less than 90 ml/min as calculated by Cockcroft-Gault equation Hemoglobin <12 mg/dL or hematocrit < 36% Abnormal liver function tests, including Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin, Albumin, and Alkaline Phosphatase Weight < 34 kg History of renal dysfunction, liver dysfunction, congestive heart failure, deep venous thrombosis, breast cancer, endometrial cancer, or cervical cancer Pregnant or breast feeding On medications known to affect the reproductive axis within 3 months of the study (including oral contraceptive pills, metformin, and spironolactone) Are currently participating in another study or have been in one in the last 30 days Subjects using restricted medication (see restrictions below) are excluded unless the subject's primary care provider approves stopping the medication
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  Cardiovascular Disease Dyslipidemia Insulin Resistance Inflammation 65 years old Non-smoking Agrees to abstain from alcohol and dietary supplements during the study Willing to consume all study foods as instructed  History of heart disease, cerebrovascular disease, peripheral vascular disease, bleeding disorder, liver or renal disease, lung disease, diabetes, Human immunodeficiency virus (HIV), or cancer (other than skin cancer) in the last 5 years Body mass index (BMI) > 35 kg/m2 or < 20 kg/m2 Not weight stable Abnormal thyroid stimulating hormone Blood pressure > 150/90 Fasting blood sugar >126 mg/dl Fasting triglyceride levels >500 mg/dl Total and LDL cholesterol >95th percentile for age and sex Pregnant or breastfeeding
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 7.0-14.0,  Polycystic Ovary Syndrome Hyperandrogenism Normal Puberty Female volunteers in early to mid-puberty (i.e., late Tanner I [estradiol level > 20 pg/mL], Tanner II, or Tanner III) Premenarcheal  Pregnancy Inability to comprehend what will be done during the study or why it will be done Hemoglobin less than 12 g/dl and hematocrit less than 36% Persistently abnormal sodium, potassium, or bicarbonate (i.e., confirmed on repeat) Persistently elevated creatinine, hepatic transaminases, or alkaline phosphatase (i.e., confirmed on repeat) Total bilirubin > 1.5 times upper limit of normal (i.e., confirmed on repeat) Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure; asthma requiring intermittent systemic corticosteroids; etc.) Untreated hypo or hyperthyroidism, reflected by persistently abnormal thyroid-stimulating hormone (TSH) values Total testosterone > 200 ng/dl
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Thyroid Cancer Hashimotos Thyroiditis All patients undergoing thyroidectomy for a variety of indications at University of Texas Medical Branch in Galveston between June 2011-May 2012 Age 18-80 years old  History of previous radiotherapy to head and neck and History of radioactive iodine therapy
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 13.0-17.0,  Polycystic Ovary Syndrome Hyperandrogenism Girls ages 13 to 17 Tanner IV or V stage of puberty Post-menarche Hyperandrogenemic (total testosterone > 0.4 ng/mL or free testosterone > 35 pmol/L) with or without hirsutism Normal aspartate aminotransferase/alanine aminotransferase (AST/ALT) (AST < 35 U/L, ALT < 55 U/L) Hemoglobin > 12 mg/dL or Hematocrit > 36% Normal screening labs (with exception of the expected hormonal abnormalities inherent in hyperandrogenemia) Sexually active subjects must agree to abstain or use double barrier contraception during the study Subjects must agree not to take any other medications during the course of the study without approval by the study investigators  Abnormal screening labs (with the exception of the expected hormonal abnormalities inherent in hyperandrogenemia) Elevated AST/ALT (AST > 35 U/L, ALT > 55 U/L) Hemoglobin <12 mg/dL or hematocrit < 36% Weight < 32 kg History of liver disease, peanut allergy, deep venous thrombosis, breast cancer, endometrial cancer, or cervical cancer Pregnant or breastfeeding On medications known to affect the reproductive axis within 3 months of the study (including oral contraceptive pills, metformin, and spironolactone) On medications known or likely to inhibit or induce CYP1A2 or CYP3A4 (please see "Restrictions on use of other drugs or treatments" section below for common examples of such drugs) Are currently participating in another study or have been in one in the last 30 days